Emerging evidence indicates that tumor with elevated TMB generates increased neoantigens, which enhances T cell recognition and correlates with better outcomes following ICIs (such as PD-1/PD-L1 and CTLA-4 inhibitors) (73). This evidence concerns the gene CD274 and neoplasm.